Collegium Pharmaceutical (COLL) Gross Profit (2016 - 2026)

Collegium Pharmaceutical has reported Gross Profit for 11 years, with the latest figure at $110.3 million in Q2 2026.

• On a quarterly basis, Gross Profit rose 1.76% year-over-year to $110.3 million in Q2 2026; TTM through Jun 2026 was $485.1 million, a 21.03% increase from a year earlier, with the FY2025 full-year figure at $463.3 million, up 22.77% from the prior year.
• Gross Profit was $110.3 million for Q2 2026 at Collegium Pharmaceutical, down from $117.2 million in the prior quarter.
• The five-year high for Gross Profit was $129.2 million in Q3 2025, with the low at $48.5 million in Q1 2022.
• Average Gross Profit over 5 years is $89.1 million, with a median of $93.0 million recorded in 2023.
• The largest YoY upside for Gross Profit was 3835.11% in 2022 against a maximum downside of 12.77% in 2022.
• Over 5 years, Gross Profit stood at $49.8 million in 2022, then surged by 90.06% to $94.6 million in 2023, then grew by 3.87% to $98.3 million in 2024, then soared by 30.61% to $128.4 million in 2025, then fell by 14.09% to $110.3 million in 2026.
• The last three Gross Profit figures came in at $110.3 million (Q2 2026), $117.2 million (Q1 2026), and $128.4 million (Q4 2025), per Business Quant data.